TickerFacts.

C4 Therapeutics, Inc. (CCCC): Revenue

Annual figures by period end, from SEC filings.

$35.95M
Year ended 2025-12-31
$35.04M
Trailing 12 months to 2026-06-30
+5.0%
3-year compound annual growth
$45.78M2021-12-31: $45.78M2022-12-31: $31.10M2023-12-31: $20.76M2024-12-31: $35.58M2025-12-31: $35.95M$35.95M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$35.95M+1.0%2026-02-26, From 2025-01-01
2024-12-31$35.58M+71.4%2026-02-26, From 2024-01-01
2023-12-31$20.76M-33.3%2025-02-27, From 2023-01-01
2022-12-31$31.10M-32.1%2024-02-22, From 2022-01-01
2021-12-31$45.78Mn/a2023-02-23, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
C4 Therapeutics, Inc. (CCCC)2025-12-31$35.95M+1.0%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$35.11Mn/m
Precision Biosciences Inc (DTIL)2025-12-31$34.26M-50.1%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$39.55M-31.6%
Voyager Therapeutics, Inc. (VYGR)2025-12-31$40.37M-49.5%
Editas Medicine, Inc. (EDIT)2025-12-31$40.52M+25.4%
Scilex Holding Co (SCLX)2025-12-31$30.25M-46.5%
Fennec Pharmaceuticals Inc. (FENC)2025-12-31$44.64M-6.1%

Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗